サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1624445

核医学/放射性医薬品の世界市場規模：用途別、手技数別、タイプ別、地域別、範囲および予測　

Global Nuclear Medicine/Radiopharmaceuticals Market Size By Application, By Procedural Volume, By Type, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
核医学/放射性医薬品の世界市場規模：用途別、手技数別、タイプ別、地域別、範囲および予測　
出版日: 2024年10月11日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

核医学/放射性医薬品の市場規模と予測

核医学/放射性医薬品市場規模は、2020年に65億6,000万米ドルと評価され、2021年から2028年にかけてCAGR 9.47%で成長し、2028年には135億3,000万米ドルに達すると予測されます。

神経学的用途における放射性医薬品の需要が、予測期間中の核医学/放射性医薬品市場の成長を促進します。核医学/放射性医薬品の世界市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の核医学/放射性医薬品市場の定義

診断目的で患者に投与され、特定の画像診断装置を介してモニターされる放射性化合物は、放射性医薬品として知られています。放射性医薬品は治療や診断目的で使用されます。放射性医薬品は主に有機分子に放射性同位元素を結合させたものです。過去50年間、核医学は、化学分野への投資の増加と放射性核種および放射性標識化合物の開発により大きく発展してきました。

核医学/放射性医薬品の世界市場概要

核医学/放射性医薬品の世界市場の成長は、対象疾患の発生件数と有病率の増加によって牽引されています。アルファ線免疫療法に基づく標的がん治療の需要が増加しており、そのため世界の核医学/放射性医薬品市場は急速なペースで成長しています。

しかし、いくつかの抑制要因が世界の核医学/放射性医薬品市場の成長を制限しています。放射性医薬品の寿命が短いことが、世界の核医学/放射性医薬品市場の成長を後退させる可能性があります。また、機器価格が高いことも、世界の核医学/放射性医薬品市場の成長を阻害する可能性があります。

目次

第1章 世界の核医学/放射性医薬品市場のイントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 世界の核医学／放射性医薬品市場の展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 核医学／放射性医薬品の世界市場：用途別

  • 概要
  • 診断用途
    • SPECT用途
  • その他のSPECT用途
    • PET用途
    • 治療用途
    • 甲状腺
    • 骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他の治療用途

第6章 核医学／放射性医薬品の世界市場：手技数別

  • 概要
  • 診断手技
    • SPECT放射性医薬品
    • PET放射性医薬品
  • 治療手技
    • ベータ線エミッター
    • アルファ線放出核種
    • ブラキセラピー用アイソトープ

第7章 世界の核医学／放射性医薬品市場：タイプ別

  • 概要
  • 診断用核医学
    • SPECT放射性医薬品
  • PET放射性医薬品
    • F-18
    • ルビジウム82
    • その他のPETアイソトープ
  • 治療用核医学/放射性医薬品
    • ベータ線放出核種
    • アルファ線放出核種
    • ブラキセラピー用アイソトープ

第8章 核医学／放射性医薬品の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州地域別
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 世界の核医学/放射性医薬品市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略

第10章 企業プロファイル

  • Cardinal Health, Inc.
  • Mallinckrodt PLC
  • GE Healthcare（A Fully-Owned Subsidiary of General Electric Company）
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging S.P.A
  • Eczacibasi-Monrol Nuclear Products
  • Nordion, Inc.（A Subsidiary of Sterigenics International LLC.）
  • Advanced Accelerator Applications S.A.
  • Iba Molecular

第11章 付録

  • 関連レポート
目次
Product Code: 24378

Nuclear Medicine/Radiopharmaceuticals Market Size And Forecast

Nuclear Medicine/Radiopharmaceuticals Market size was valued at USD 6.56 Billion in 2020 and is projected to reachUSD 13.53 Billion by 2028, growing at aCAGR of 9.47% from 2021 to 2028.

The demand for radiopharmaceuticals in neurological applications will drive the growth of the Nuclear Medicine/Radiopharmaceuticals Market during the forecast period. The Global Nuclear Medicine/Radiopharmaceuticals Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nuclear Medicine/Radiopharmaceuticals Market Definition

The radioactive compounds administered to the patient and monitored via a specific imaging device for diagnostic purposes are known as radiopharmaceuticals. This drug can be used for therapeutic or diagnostic purposes. The radiopharmaceuticals are mainly composed of a radioisotope bond to an organic molecule. Over the last 50 years, nuclear medicine has developed significantly owing to increasing investments in the field of chemistry and the development of radionuclides and radiolabeled compounds.

Global Nuclear Medicine/Radiopharmaceuticals Market Overview

The growth of the global Nuclear Medicine/Radiopharmaceuticals Market is being driven by increasing incidences and prevalence of target conditions. The demand for alpha radioimmunotherapy-based targeted cancer treatment is increasing and owing to which the global Nuclear Medicine/Radiopharmaceuticals Market is flourishing at a rapid pace.

However, some restraints are liming the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. The short life span of radiopharmaceuticals may create setbacks for the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. Also, the high equipment prices may hamper the growth of the global Nuclear Medicine/Radiopharmaceuticals Market.

Global Nuclear Medicine/Radiopharmaceuticals Market: Segmentation Analysis

The Global Nuclear Medicine/Radiopharmaceuticals Market is Segmented on the basis of Application, Procedural Volume, Type, and Geography.

Nuclear Medicine/Radiopharmaceuticals Market, By Application

  • 1.1 Diagnostic Applications
    • 1.1.1 SPECT Applications
    • 1.1.1.1 Cardiology
    • 1.1.1.2 Neurology
    • 1.1.1.3 Thyroid
  • 1.2 Other SPECT Applications
    • 1.2.1 PET Applications
    • 1.2.1.1 Oncology
    • 1.2.1.2 Cardiology
    • 1.2.1.3 Neurology
    • 1.2.1.4 Other PET Applications
    • 1.2.2 Therapeutic Applications
    • 1.2.3 Thyroid
    • 1.2.4 Bone Metastasis
    • 1.2.5 Lymphoma
    • 1.2.6 Endocrine Tumors
    • 1.2.7 Other Therapeutic Applications

Based on Application, the market is segmented into Diagnostic Applications and Other SPECT Applications. The diagnostic applications dominated the global Nuclear Medicine/Radiopharmaceuticals Market. The SPECT applications especially contributed majorly to the growth of the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

  • 2.1 Diagnostic Procedures
    • 2.1.1 SPECT Radiopharmaceuticals
    • 2.1.2 PET Radiopharmaceuticals
  • 2.2 Therapeutic Procedures
    • 2.2.1 Beta Emitters
    • 2.2.2 Alpha Emitters
    • 2.2.3 Brachytherapy Isotopes

Based on Procedural Volume, the market is segmented into Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures are further bifurcated into SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, and Therapeutic Procedures. The Therapeutic Procedures are further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The Diagnostic Procedures dominated the global Nuclear Medicine/Radiopharmaceuticals Market.

Nuclear Medicine/Radiopharmaceuticals Market, By Type

  • 3.1 Diagnostic Nuclear Medicine
    • 3.1.1 SPECT Radiopharmaceuticals
    • 3.1.1.1 Tc-99m
    • 3.1.1.2 Tl-201
    • 3.1.1.3 Ga-67
    • 3.1.1.4 I-123
    • 3.1.1.5 Other SPECT Isotopes
  • 3.3 PET Radiopharmaceuticals
    • 3.2.1 F-18
    • 3.2.2 Rubidium-82
    • 3.2.3 Other PET Isotopes
  • 3.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
    • 3.3.1 Beta Emitters
    • 3.3.1.1 Iodine-131
    • 3.3.1.2 Y-90
    • 3.3.1.3 Sm-153
    • 3.3.1.4 Re-186
    • 3.3.1.5 Lu-177
    • 3.3.1.6 Other Beta Emitters
    • 3.3.2 Alpha Emitters
    • 3.3.2.1 Ra-223
    • 3.3.3 Brachytherapy Isotopes
    • 3.3.3.1 Iodine-125
    • 3.3.3.2 Iridium-192
    • 3.3.3.3 Palladium-103
    • 3.3.3.4 Cesium-131
    • 3.3.3.5 Other Brachytherapy Isotopes

Based on Type, the market is segmented into Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, and Therapeutic Nuclear Medicine/Radiopharmaceuticals. The Therapeutic Nuclear Medicine/ Radiopharmaceuticals is further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The alpha emitters segment dominated the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on regional analysis, the Global Nuclear Medicine/Radiopharmaceuticals Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The dominance of the North American region can be attributed to the development of novel technologies for radioscopic production and an increase in government funding.

Key Players

  • The "Global Nuclear Medicine/Radiopharmaceuticals Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Cardinal Health, Inc., Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Advanced Accelerator Applications S.A., Iba Molecular.
  • These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Key Developments

  • Partnerships, Collaborations and Agreements
  • A manufacturing and distribution deal was signed in 2019 between Eczacba-Monrol and Telix Pharmaceuticals Limited (Australia). Telix has engaged Eczacba-Monrol as a radiopharmaceutical production partner and distributor throughout Turkey, the Middle East, and North Africa, according to the conditions of the agreement.
  • Mergers and Acquisitions
  • In the year 2019, Curium acquired MAP Medical, allowing it to expand its footprint in Europe and gain direct access to the Nordic and Baltic countries.
  • Product Launches and Product Expansions
  • Curium (France) and NRG (Netherlands) inked a Molybdenum-99 manufacturing agreement in 2019.
  • Cobalt-60 was purchased from the Board of Radiation and Isotope Technology (BRIT) in April 2019 for distribution throughout Europe by Nordion, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 Diagnostic Applications
    • 5.2.1 SPECT Applications
    • 5.2.1.1 Cardiology
    • 5.2.1.2 Neurology
    • 5.2.1.3 Thyroid
  • 5.3 Other SPECT Applications
    • 5.3.1 PET Applications
    • 5.3.1.1 Oncology
    • 5.3.1.2 Cardiology
    • 5.3.1.3 Neurology
    • 5.3.1.4 Other PET Applications
    • 5.3.2 Therapeutic Applications
    • 5.3.3 Thyroid
    • 5.3.4 Bone Metastasis
    • 5.3.5 Lymphoma
    • 5.3.6 Endocrine Tumors
    • 5.3.7 Other Therapeutic Applications

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 6.1 Overview
  • 6.2 Diagnostic Procedures
    • 6.2.1 SPECT Radiopharmaceuticals
    • 6.2.2 PET Radiopharmaceuticals
  • 6.3 Therapeutic Procedures
    • 6.3.1 Beta Emitters
    • 6.3.2 Alpha Emitters
    • 6.3.3 Brachytherapy Isotopes

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1 Overview
  • 7.2 Diagnostic Nuclear Medicine
    • 7.2.1 SPECT Radiopharmaceuticals
    • 7.2.1.1 Tc-99m
    • 7.2.1.2 Tl-201
    • 7.2.1.3 Ga-67
    • 7.2.1.4 I-123
    • 7.2.1.5 Other SPECT Isotopes
  • 7.3 PET Radiopharmaceuticals
    • 7.3.1 F-18
    • 7.3.2 Rubidium-82
    • 7.3.3 Other PET Isotopes
  • 7.4 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
    • 7.4.1 Beta Emitters
    • 7.4.1.1 Iodine-131
    • 7.4.1.2 Y-90
    • 7.4.1.3 Sm-153
    • 7.4.1.4 Re-186
    • 7.4.1.5 Lu-177
    • 7.4.1.6 Other Beta Emitters
    • 7.4.2 Alpha Emitters
    • 7.4.2.1 Ra-223
    • 7.4.3 Brachytherapy Isotopes
    • 7.4.3.1 Iodine-125
    • 7.4.3.2 Iridium-192
    • 7.4.3.3 Palladium-103
    • 7.4.3.4 Cesium-131
    • 7.4.3.5 Other Brachytherapy Isotopes

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 EuropeRegional
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Cardinal Health, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Mallinckrodt PLC
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Lantheus Medical Imaging, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bayer AG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bracco Imaging S.P.A
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Eczacibasi-Monrol Nuclear Products
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Advanced Accelerator Applications S.A.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Iba Molecular
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Reports